S&P Futures
4,170.75 -5.00 (-0.12%) Dow Futures
34,168.00 -38.00 (-0.11%) Nasdaq Futures
12,764.50 -12.25 (-0.10%) Russell 2000 Futures
1,975.10 -4.20 (-0.21%) Crude Oil
77.18 +0.04 (+0.05%) Gold
1,889.20 +4.40 (+0.23%)
Aethlon Medical, Inc. (AEMD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6206 |
| Open | 0.6256 |
| Bid | 0.5821 x 900 |
| Ask | 0.6200 x 1000 |
| Day's Range | 0.5781 - 0.6500 |
| 52 Week Range | 0.2300 - 2.4600 |
| Volume | |
| Avg. Volume | 1,113,159 |
| Market Cap | 13.534M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7060 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.
- PR Newswire
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.
- Zacks Small Cap Research
AEMD: Hemopurifier Hemopurifier To Be Studied in a Variety of Solid Tumors
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the
